Shape Therapeutics will showcase multiple presentations at ASGCT 2025, including data demonstrating up to 88% targeted RNA editing in primate brain using systemically delivered AAV5-based capsid variants.
Arbor Biotechnologies' ABO-101, a CRISPR-based gene editing therapy, has been cleared by the FDA for a Phase 1/2 clinical trial in primary hyperoxaluria type 1 (PH1).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.